Fri, January 22, 2021

Brian Abrahams Maintained (BCRX) at Hold with Increased Target to $9 on, Jan 22nd, 2021

Brian Abrahams of RBC Capital, Maintained "BioCryst Pharmaceuticals, Inc." (BCRX) at Hold with Increased Target from $7 to $9 on, Jan 22nd, 2021.

Brian has made no other calls on BCRX in the last 4 months.



There are 2 other peers that have a rating on BCRX. Out of the 2 peers that are also analyzing BCRX, 0 agree with Brian's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Brian


  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $14 on, Monday, December 7th, 2020
  • Liisa Bayko of "Evercore ISI Group" Initiated at Buy and Held Target at $12 on, Tuesday, November 24th, 2020